
    
      This is a long term, multicenter, open-label, safety extension study in subjects with partial
      onset seizures who have just completed, discontinued, or exited the 18-week treatment phase
      of Protocols 093-045 or 093-046. The initial study duration is 1 year with the option of
      continuing study drug treatment post 1 year until a subject discontinues study, the study
      drug becomes clinically available in the subject's locale, or the sponsor terminates the
      study drug clinical development program.

      This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired
      by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to
      Sunovion Pharmaceuticals Inc.
    
  